Hopeful law firms in search of plaintiffs for kickback suits against Sanofi

Sanofi ($SNY) made its fair share of bad headlines in the latter half of 2014, and law firms are hoping that means one thing: plaintiffs for shareholder lawsuits against the French drugmaker. Potential claims focus on an alleged illegal kickback strategy for the company's diabetes franchise, designed to boost sales. More

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.